ABCAM PLC Notice of Results (7579Y)
11 September 2020 - 7:34PM
UK Regulatory
TIDMABC
RNS Number : 7579Y
ABCAM PLC
11 September 2020
11September 2020
ABCAM PLC
("Abcam," the "Company" or the "Group")
Notice of Full Year Results
Abcam plc (AIM: ABC), a global leader in the supply of life
science research tools, will report its Full Year Results for the
twelve-month period ended 30 June 2020 on 14 September 2020.
Abcam will host a webcast for analysts and investors at midday
BST / 7am EDT that day, with an opportunity to ask questions via
the conference call line. To register, please contact Mary Whittow
at FTI Consulting (Mary.Whittow@fticonsulting.com / +44 (0) 20 3327
1366). Alternatively, details are available via the Investor
Relations section of Abcam's website at
www.abcamplc.com/investors/reports-presentations/
A replay will also be made available on the Company's website
following the event.
Abcam plc
+ 44 (0) 1223 696 000
James Staveley, VP Investor Relations
Numis - Nominated Adviser & Joint Corporate Broker
+ 44 (0) 20 7260 1000
Garry Levin / Duncan Monteith / Huw Jeremy
J.P.Morgan Cazenove - Joint Corporate Broker
+44 (0) 20 7742 4000
James Mitford / Hemant Kapoor
Morgan Stanley - Joint Corporate Broker
+ 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting
+44 (0) 20 3727 1000
Ben Atwell / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Group offers highly validated
antibodies and assays to address important targets in critical
biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Group continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
Please visit www.abcam.com or www.abcamplc.com to find out
more.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGCGDCDXBDGGB
(END) Dow Jones Newswires
September 11, 2020 05:34 ET (09:34 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024